Pharmaceuticals, Biotechnology and Life Sciences
Odonate Therapeutics on Monday announces completion of enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic…
WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $500 million in aggregate…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients…
Genentech’s Tecentriq’s First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the…
Verseau has launched with $50M to work on PSGL-1, which has been identified as lead macrophage checkpoint modulator (MCM) program…
Circassia Pharmaceuticals Inc. has launched Duaklir, aclidinium bromide and formoterol fumarate, for the maintenance treatment of patients with chronic obstructive…
Merck has received positive EU CHMP opinion for two new regimens of Keytruda (pembrolizumab) as first-line ttreatment for metastatic or…
Merck has received EU CHMP positive opinion for investigational V920 ebola Zaire vaccine for protection Against ebola virus disease.
Cytel Inc., the leading global provider of innovative analytical software and consulting services to the life sciences industry, has announced its Complex Innovative Trial Design Symposium and East Training event, which will bring together industry-leading experts to discuss innovative solutions to pressing challenges including rare disease clinical trials, and will also offer delegates an in-depth East software training session.
The FDA has accepted for review Foamix’s New Drug Application (NDA) for FMX103 (minocycline topical foam 1.5%) topical foam, for the treatment of moderate-to-severe papulopustular rosacea in adults.